Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908024 · ClinicalTrials.gov registry record · Phase 1
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00908024 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 54 participants.
The verdict
NCT00908024, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies. The study is also intended to collect first data on the effects of the combination of BMS-754807 with cetuximab on tumors of patients with colorectal cancer or squamous cell cancer of the head and neck for whom cetuximab-containing therapies have not been effective
Interventions
- DRUG BMS-754807
- DRUG cetuximab (Erbitux®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00908024
The ClinicalTrials.gov registry entry for NCT00908024 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-754807 is the first listed.
NCT00908024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00908024 about?
NCT00908024 is a clinical study titled "Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors". The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies. The study is also intended to collect first data on the effects of the combination of BMS-754807 with cetuximab on tum...
What is the current status of trial NCT00908024?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2009-10. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00908024?
The interventions under investigation include: BMS-754807 (DRUG), cetuximab (Erbitux®) (DRUG).
Who is sponsoring clinical trial NCT00908024?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.